Tetrous earns patent for bone fiber implants

Tetrous, a start-up focused on bone-to-tendon healing following orthopedic surgery, has earned a fourth patent related to its EnFix family of demineralized cortical bone fiber implants.

Advertisement

The EnFix family of products is designed to enhance healing at the tendon-to-bone interface, according to an Oct. 15 press release. 

The implants provide osteoinductivity and osteoconductivity, while Tetrous’ “FormLok” technology gives the device shape retention, even in the wet environment of arthroscopic surgery.

The newly issued patent is titled “Demineralized Bone Fiber Implant Compositions and Methods for Rotator Cuff and ACL Repair.”

More than 700 EnFix RC and EnFix TAC implants have been implanted in the U.S. and Australia since July 1, 2023, according to the release.

Advertisement

Next Up in Biologics

  • Regenerative medicine company Auragens has opened an orthobiologics division.  Orthopedic surgeon Abdiel Ortiz, MD, will lead the new division, which…

  • So far this year, medtech companies and academic institutions are making key strides in spine biologics. From new product launches…

Advertisement

Comments are closed.